Enjoy complimentary customisation on priority with our Enterprise License!
The global hemostats and tissue sealants market size is estimated to grow by USD 2.55 billion at a CAGR of 10.18% between 2022 and 2027. High use of hemostats and tissue sealants in surgeries. Adverse events such as bleeding and leakage of body fluids are involved in surgical procedures. The clinical consequences can lead to an increased risk of organ failure. These sealants are used in minimally invasive surgeries. Clinicians who are performing minimally invasive surgeries encounter internal hemorrhage. Furthermore, the efficient use of hemostasis and tissue sealing agents can also help control such events. As a result, hemostats and tissue sealants are extensively used in minimally invasive surgeries and percutaneous interventional procedures. This market research and growth report also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
Technavio has segmented the market into Product, End-user, and Geography. The market cater to the demand for effective solutions in managing bleeding and preventing hemorrhage during injuries, surgical procedures, and in the geriatric population with chronic conditions. The American population, particularly those with chronic diseases such as diabetes, cancer, cardiovascular diseases, and neurological disorders, significantly contribute to the market growth. Critical care situations, including slow-healing injuries, spinal injuries, ophthalmic injuries, and urological disorders, also require their use. Market leaders like Ethicon, a subsidiary of Johnson & Johnson, offer products such as GELFOAM Sterile Sponge, a mechanical hemostat which forms a mechanical barrier to stop blood flow and accelerate clotting. Other surgical products, including adhesives and tissue-sealing agents, are also in demand for minimally invasive surgeries in urology and cardiac diseases. Despite the market's potential, lack of reimbursements and adverse reactions or complications can pose challenges. Market concentration and healthcare professionals' preferences play a significant role in the global presence of these products.
Hemostats
The market share growth by the hemostats segment will be significant during the forecast period. A hemostat is a medical device used to achieve hemostasis by accelerating the clotting of blood. They are most frequently used to stop non-cauterized, non-saturable bleeding. There are four categories in particular that have been defined by their mechanical, active, and flowable forms.
Get a glance at the market contribution of various segments View a PDF Sample
The hemostats segment was valued at USD 1.91 billion in 2017. Mechanical hemostats are based on gelatin, collagen, cellulose, and polysaccharides. They are applied as sponges and do not contain thrombin or any other active biologic compounds. The active hemostat is a topical thrombin that stimulates the fibrinogen at the site of bleeding to cause clot formation. Flowable hemostatic agents are typically composed of either a porcine or bovine gelatin matrix and thrombin.
Hospitals
The hospitals segment plays a significant segment in the global market. Hospitals perform a wide range of surgical procedures, including cardiovascular surgeries, orthopedic surgeries, general surgeries, and gynecological surgeries, among others. Hemostasis and tissue-sealing agents are commonly required during these procedures for the purpose of controlling bleeding and sealing tissues. Hospitals, with their high surgical volume, are major consumers of these products. Hemostats are widely used in emergency departments to quickly stop bleeding in trauma patients and facilitate the stabilization process. The number of people is increasing, which means that more patients need to be surgically treated. There is also a corresponding increase in hospital surgery as the population grows. Hospitals handle a significant portion of these surgical procedures, driving the demand for hemostats and tissue sealants. Such factors are expected to drive the growth of the hospital segment of the global market during the forecast period.
Ambulatory surgical centers
Ambulatory surgical centers (ASCs) are healthcare facilities that provide same-day surgical care to patients, allowing them to undergo surgical procedures and return home on the same day. With its cost-effectiveness, convenience, and efficiency in healthcare delivery, ambulatory surgery centers have become very popular over the last few years. The increasing utilization of ASCs for various surgical procedures, including minimally invasive surgeries, orthopedic surgeries, ophthalmic surgeries, and cosmetic surgeries, drives the demand in these facilities. In ASCs, hemostats and tissue sealants are required for the purpose of controlling blood flow and promoting tissue sealing so as to avoid complications and increase patients' quality of life. Manufacturers are developing innovative products with enhanced properties such as rapid hemostasis, strong sealing capabilities, reduced tissue trauma, and minimal adverse reactions, catering specifically to the needs of ASCs. Demand for hemostasis and tissue sealing agents in these centers is driven by the growing number of ASCs, as well as a corresponding increase in outpatient surgical procedures. Such factors are expected to drive the growth of the ASCs segment of the global market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The US and Canada is the leading contributor to the growth of the hemostats and tissue sealants market in North America. Advanced medical infrastructure and an increasing number of surgical procedures are the key factors driving the growth of the market in this region. Furthermore, nearly 6 million spinal, cardiovascular, abdominal, and other major bleeding surgeries are performed in the US each year.
The European approval of various hemostats and tissue sealant products contributes to the growth of this market. Terumo's AQUABRID is one such approved product. Regulations and product substitutes, such as sutures, staples, energy-based devices, and coagulation systems, also impact market size. In Europe, general surgery, hospitals, and specialty clinics utilize various types of hemostats and tissue sealants, including gelatin-based and collagen-based topical hemostats, fibrin sealant products, synthetic tissue sealants, and natural tissue sealants. Hemophilia and Immune Thrombocytopenia patients benefit from these products. Market segments include mechanicals, flowable, active hemostats, and adhesion barrier products.
Buy Now Full Report and Discover More
The market encompasses a range of products used to control bleeding during surgical procedures in the geriatric population, who often have chronic conditions requiring critical care. These products include sutures, staples, hemostats, adhesives, fibrin sealant products, and topical hemostats. These find applications in various surgical procedures, such as hernia fixation, spinal injuries, ophthalmic injuries, urological disorders, burns, and minimally invasive surgeries. Companies like Ethicon, a Johnson & Johnson subsidiary, and Terumo have gained European approval for their hemostat and tissue sealant offerings. However, lack of reimbursements and adverse reactions pose challenges to market growth. Regulations governing product substitutes and the use of energy-based devices in general surgery also impact market dynamics. Hemophilia and immune thrombocytopenia patients benefit from specialized coagulation system hemostats and sealants. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The increasing prevalence of chronic diseases and their related risk factors is driving the growth of the global market. Approximately 25 million surgical procedures are conducted monthly worldwide, many of which result in bleeding and fluid leakage. These complications can lead to hemodynamic instability, hypovolemia, anemia, and decreased oxygen delivery to vital tissues, increasing the risk of organ failure. They play crucial roles in addressing these issues. They help control bleeding and seal suture lines, respectively, during surgeries. These products are particularly beneficial for the geriatric population and those with chronic conditions, including diabetes, cancer, and cardiovascular diseases.
In critical care settings, they are essential for managing injuries, wounds, and complications from hernia fixation, spinal injuries, ophthalmic injuries, urological disorders, burns, and minimally invasive surgeries. Despite their importance, market concentration and lack of reimbursements pose challenges. Ethicon, a Johnson & Johnson company, is a notable player in this field. These agents are indispensable in cardiovascular surgeries and other medical specialties, such as neurology and urology. However, adverse reactions and complications associated with their use remain concerns.
The growth of oncology tourism is a primary trend in the market. The market encompasses innovative solutions designed to address bleeding and prevent hemorrhage during injuries, surgical procedures, and in critical care settings. With an aging population and a rise in chronic conditions, there is a growing demand for effective hemostats and tissue sealants in the American population and globally. Companies such as Baxter International are expanding their product offerings, introducing next-generation hemostats and sealants, and pursuing additional indications for their existing products. For instance, Baxter's advanced hemostats and sealants have been launched for use in various surgical procedures, including cardiovascular surgeries and hernia fixation. 3-D Matrix Medical Technology is focusing on the development of synthetic hemostatic materials, like PuraStat, a prefilled syringe indicated for reducing delayed bleeding following gastrointestinal endoscopic submucosal dissection procedures.
Other chronic conditions, such as diabetes, cancer, cardiovascular diseases, neurological diseases, and urological disorders, also necessitate the use of these in their management. Despite the market's potential, challenges persist, including a lack of reimbursements and adverse reactions or complications. Ethicon, a Johnson & Johnson company, is a key player in this market, offering a range of hemostats, adhesives, and tissue-sealing agents. The market concentration is high, with a few major players dominating the landscape. Healthcare professionals rely on these companies' global presence and advanced product offerings to address the diverse needs of patients with various injuries and conditions.
Stringent government regulations regarding the manufacturing of these sealants are a significant challenge that affects the growth of the market. The global market faces limitations due to the high costs associated with advanced products. Bleeding and hemorrhage are common challenges during surgical procedures for the geriatric population and those with chronic conditions. Injuries, wounds, and complications from diabetes, cancer, cardiovascular diseases, hernia fixation, spinal injuries, ophthalmic injuries, and urological disorders can lead to slow-healing injuries. Hemostats, adhesives, and tissue-sealing agents are essential in managing bleeding and promoting healing. However, the lack of reimbursements and high per-unit costs, ranging from USD 50 to USD 600 for fibrin sealants and USD 200 to USD 300 for active flowable hemostats, restrict market growth. Critical care patients, including older patients and those with neurological and urological diseases, require these products. Ethicon, a Johnson & Johnson company, is a significant player in this market. Despite the market concentration, healthcare professionals continue to seek effective solutions for minimally invasive surgeries and cardiovascular procedures. Adverse reactions and complications remain concerns.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Advanced Medical Solutions Group Plc - The company offers hemostats and tissue sealants under the brands, such as LiquiBand and ActivHeal.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market encompasses products used for controlling bleeding and promoting tissue healing. These essential medical devices find extensive applications in various surgical procedures. The market is driven by the increasing number of surgeries worldwide and the rising prevalence of chronic diseases. Hemostats are used to control bleeding during surgical procedures by applying pressure to the wound site. Tissue Sealants, on the other hand, promote tissue healing by filling the gaps between damaged tissues and creating a seal. Both these products play a crucial role in minimizing blood loss and ensuring faster recovery. The market is segmented based on product type, application, and end-users.
The product type segment includes Hemostats and Tissue Sealants. The application segment includes Cardiovascular Surgeries, Neurosurgeries, Orthopedic Surgeries, and others. The end-users segment includes Hospitals, Ambulatory Surgical Centers, and others. The market is expected to grow significantly due to the increasing number of surgeries and the rising prevalence of chronic diseases. The market is also driven by the technological advancements in these products, which are leading to the development of more effective and efficient solutions. In conclusion, the market is a growing and dynamic industry that plays a vital role in healthcare. The market is driven by the increasing number of surgeries, the rising prevalence of chronic diseases, and the technological advancements in these products.
The market analysis and report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Market Scope |
|
Report Coverage |
Details |
Page number |
171 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.18% |
Market growth 2023-2027 |
USD 2.55 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
9.63 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Advanced Medical Solutions Group Plc, B.Braun SE, Baxter International Inc., Becton Dickinson and Co., BioCer Entwicklungs GmbH, Cardinal Health Inc., CSL Ltd., CuraMedical BV, Hemostasis LLC, Integra Lifesciences Corp., Johnson and Johnson Services Inc., KATSAN KATGUT SANAYI VE TICARET A.S, Medtronic Plc, Pfizer Inc., Smith and Nephew plc, Stryker Corp., Teijin Ltd., Teleflex Inc., Tricol Biomedical Inc., and Vivostat AS |
Market dynamics |
Parent market trends and analysis, Market growth and trends and inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.